June 21 (Reuters) - The U.S. Food and Drug Administration has approved Bristol Myers Squibb's combination therapy for treating colorectal cancer patients with a specific gene mutation, the health regulator's website showed on Friday. (Reporting by Christy Santhosh, Unnamalai L and Puyaan Singh in Bengaluru; Editing by Shilpi Majumdar)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
40.06 USD | -0.96% | -3.49% | -21.93% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.93% | 81.21B | |
+54.07% | 809B | |
+38.95% | 621B | |
-7.05% | 351B | |
+15.44% | 319B | |
+5.72% | 289B | |
+14.21% | 238B | |
-0.45% | 221B | |
+14.58% | 218B | |
+7.42% | 166B |
- Stock Market
- Equities
- BMY Stock
- News Bristol-Myers Squibb Company
- US FDA approves Bristol Myers' colorectal cancer therapy